Juanita Fleming
Adult Medicine · Pensacola, FLNPI 1740406289
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $689 and has fallen 64.4% since, to $245 in 2025.
Across 128 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$460
- Dexcom, Inc.$331
- AbbVie$309
- Novo Nordisk$294
- Pfizer$208
- AstraZeneca$177
- plus $836 from 15 others
What the payments were for
- Food & beverage$2,615100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $460 |
| Dexcom, Inc. | 8 | $331 |
| AbbVie(2 entities) | 15 | $309 |
| Novo Nordisk | 12 | $294 |
| Pfizer | 25 | $208 |
| AstraZeneca | 7 | $177 |
| Novartis | 7 | $120 |
| Exact Sciences | 5 | $93 |
| Amgen | 6 | $89 |
| Gilead | 1 | $84 |
| Bayer | 4 | $75 |
| Lilly USA, LLC | 4 | $66 |
| Astellas Pharma US Inc | 3 | $65 |
| Philips North America LLC | 1 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Boehringer Ingelheim | 2 | $35 |
| Shire North American Group Inc | 2 | $34 |
| Abbott | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$124
How this compares
$2,615 in reported general payments places this provider in the 85th percentile of 195 adult medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $81,598 |
| TrulicityDulaglutide | 45 | $52,783 |
| FarxigaDapagliflozin Propanediol | 15 | $21,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $21,025 |
| JanuviaSitagliptin Phosphate | 14 | $20,584 |
| LinzessLinaclotide | 16 | $19,347 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $17,537 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $15,101 |
| JardianceEmpagliflozin | 14 | $12,677 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 204 | $5,426 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $5,120 |
| Gabapentin | 239 | $3,076 |
| Levemir FlexpenInsulin Detemir | 11 | $2,936 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 13 | $2,620 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $2,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $294 | $81,59876 claims |
| Lilly USA, LLCTrulicity | $66 | $52,78345 claims |
| AstraZenecaFarxiga, Symbicort | $177 | $37,05954 claims |
| Boehringer IngelheimGlyxambi, Jardiance | $35 | $30,21325 claims |
| GSKTrelegy Ellipta | $460 | $21,02529 claims |
| AbbVieLinzess | $309 | $19,34716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 adult medicine providers in Florida.
Other adult medicine in Pensacola
- Steven SantiagoMiami$290K
- Tammy DsouzaKissimmee$191K
- Eric SchertzerPlantation$26K
- Ricardo SerranoMerritt Island$20K
- Marlene JarinMiami Beach$18K
- Myra ReedPanama City Beach$16K
- Joshua RycusCoral Springs$13K
- Frederick WeigandDeltona$9K
- Hernando ChongMiami$9K
- Neri FranzonFt Lauderdale$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.